Radoslava Kristofova

Dr. Radoslava Kristofova

Institute of Animal Physiology, Kosice, Centre of Biosciences SAS, Bratislava, Bratislavský, Slovakia
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2025 in Animals
Verified
Journal Article
Open access
PDF file
RKRadoslava Kristofova
Radoslava Kristofova
KZKarin Zitterl-Eglseer
Karin Zitterl-Eglseer
FFFardad Firooznia
Fardad Firooznia
ALAndrea Lauková
Andrea Lauková
LCLubica Chrastinova
Lubica Chrastinova
IPIveta Plachá
Iveta Plachá
Thymol gastro-resistant self-emulsifying pellets were used to achieve thymol targeted release on the side of the intestine with the most intensive absorption to enhance its oral bioavailability. Forty-eight rabbits (35 d of age) were divided into two groups fed with a standard diet containing gastro-resistant enteric pellets (control, CG; without thymol, initial live weight 1350.0 ± 18.0, and experimental, EG; with thymol 250 mg/kg, initial live weight 1352.0 ± 19.9 g). The experiment lasted 28 days: thymol was administered for 21 days and then withdrawn for 7 days. Thymol was significantly higher in duodenal wall (DW) than in plasma during both periods (p = 0.0053, p < 0.0001). Significant correlation was established between thymol concentration in plasma and DW during its application (rs = 0.9333, p < 0.001). Thymol was below the limit of quantitation in plasma, spleen and muscle only after its withdrawal, and its significantly higher concentration in kidney and fat than in plasma (p = 0.0182, p = 0.0003) and muscle (p = 0.0236, p = 0.0004) indicates its efficient accumulation. Thymol in gastro-resistant form prevented its degradation due to adverse conditions in the stomach and ensured its release at the site of greatest absorption in the small intestine.

22 September 2023 in Italian Journal of Animal Science
Verified
Journal Article
Open access
KBKristina Bacova
Kristina Bacova
KZKarin Zitterl-Eglseer
Karin Zitterl-Eglseer
ALAndrea Lauková
Andrea Lauková
LCLubica Chrastinova
Lubica Chrastinova
SGSona Gancarcikova
Sona Gancarcikova
IPIveta Plachá
Iveta Plachá

16 November 2023 in Planta Medica
Verified
Journal Article
Closed access
IPIveta Placha
Iveta Placha
KBKristina Bacova
Kristina Bacova
RKRadoslava Kristofova
Radoslava Kristofova
Herbal remedies historically represent the first pharmacological compounds used in the treatment of many diseases. Despite being considered safer than synthetic drugs, food and drug interactions must be extensively evaluated in terms of their absorption, excretion, distribution and metabolism. Plants containing thymol have been used in traditional medicine for the treatment of various diseases, such as cardiovascular diseases, cancer and diabetes. To understand the bioavailability of thymol in animal organisms and to establish the suitable concentration for beneficial effects on animal health, its metabolic path needs to be understood at the molecular level. Oral bioavailability represents the fraction of administered thymol reaching the systemic circulation and is a key parameter that affects its efficacy. Therefore, to propose an appropriate dose, the study of thymol oral bioavailability has received significant attention. Information concerning the bioactivity of thymol and its metabolites in animal organisms could also be applied to human medicine and may help in the utilization of herbal medicine in humans and in veterinary healthcare. However, relatively few studies on the bioavailability and pharmacokinetics of thymol are available to date. According to our knowledge from the current literature, thymol metabolites, mostly thymol sulphate and glucuronide, were detected in the plasma and urine of humans and in the plasma, intestinal content, faeces and tissues in rats, pigs, chickens, horses and rabbits. To precisely understand the metabolic processes and biological activity of thymol and its metabolites within organisms, more clinical studies are necessary, with preclinical comprehensive research on animal models. Funding VEGA 2/0009/20 Article published online: 16 November 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

10 October 2026 in Animals
Verified
Journal Article
Open access
PDF file
RKRadoslava Kristofova
Radoslava Kristofova
KZKarin Zitterl-Eglseer
Karin Zitterl-Eglseer
MWMarkus Wildner
Markus Wildner
AZAndreas Zitterl
Andreas Zitterl
MSMonika Pogány Simonová
Monika Pogány Simonová
IPIveta Plachá
Iveta Plachá
The positive effect of thymol on gut health largely depends on its absorption from the intestinal tract and its biotransformation processes in the intestinal wall. A total of 32 rabbits were randomly divided at 35 days of age into a control (CG) and an experimental group (EG) that received thymol at 250 mg/kg feed. Thymol concentration was significantly higher in the caecum than in the ileum (p < 0.05), which is likely associated with caecotrophy and reduced enzymatic activity in the distal segments of the small intestine. Coliform bacteria (p = 0.0095) and lactic acid bacteria (LAB; p = 0.0002), Staphylococcus spp. (p = 0.0002), and Enterococcus spp. (p = 0.0002) in the duodenum; LAB (p = 0.0003) and Enterococcus spp. (p = 0.0002) in the ileum; and other Enterobacteriaceae (p = 0.0002) and LAB (p = 0.0068) in the caecum were significantly higher in the EG. Despite the significantly lower thymol concentration in the ileum compared to the caecum, the beneficial LAB was positively affected. A decrease in immunoglobulin A in all parts of the intestinal tract except the colon was a result of the modulation of mucosal immunity. Thymol at this concentration modulated the gut ecosystem without disrupting its beneficial components, thereby helping maintain intestinal homeostasis.

2 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RKRadoslava Kristofova
Radoslava Kristofova
KZKarin Zitterl-Eglseer
Karin Zitterl-Eglseer
FFFardad Firooznia
Fardad Firooznia
ALAndrea Lauková
Andrea Lauková
LCLubica Chrastinová
Lubica Chrastinová
IPIveta Plachá
Iveta Plachá
Thymol gastro-resistant self-emulsifying pellets were used to achieve thymol targeted release on the side of the intestine with the most intensive absorption to enhance its oral bioavailability. Forty - eight rabbits (35 d of age) were divided into two groups fed with a standard diet containing gastro-resistant enteric pellets (control, CG; without thymol and experimental, EG; with thymol 250 mg/kg). The experiment lasted 28 days; thymol was administered for 21 days and then withdrawn for 7 days. Thymol was in balance in all parts of the intestinal tract, significantly higher in duodenal wall (DW) than in plasma during both periods (p = 0.0053, p < 0.0001), and a significant correlation was established between thymol concentration in plasma and DW during thymol applica-tion (rs = 0.9333, p < 0.001), which points to the efficient release of thymol from enteric pellets in the small intestine with an intensive absorption rate. Thymol was below the limit of quantitation in plasma, spleen and muscle only after its withdrawal, and its significantly higher concentration in kidney and fat than in plasma (p = 0.0182, p = 0.0003) and muscle (p = 0.0236, p = 0.0004) indicates its efficient accumulation.

13 June 2026 in Planta Medica
Verified
Journal Article
Open access
JAJelena Arsenijević
Jelena Arsenijević
CRCéline Renouard
Céline Renouard
KBKristina Bacova
Kristina Bacova
CBCigdem Bilgi
Cigdem Bilgi
CCCarole Cousin
Carole Cousin
MMMarta Mendel
Marta Mendel
The growing urgency to reduce antimicrobial and antiparasitic use in livestock has renewed scientific interest in medicinal plants as sustainable components of veterinary healthcare. However, the absence of a dedicated regulatory framework for herbal veterinary medicinal products (HVMPs) in the European Union continues to hinder their wider application. The need for a science-based, multi-criteria framework to identify medicinal plant species as sources of active substances of herbal origin, with the highest potential for future inclusion in a dedicated EU registration pathway for HVMPs, resulted in the establishment of a multidisciplinary expert panel. The panel evaluated over 100 medicinal plant species with documented veterinary application, using a structured scoring system integrating regulatory, pharmacopoeial, toxicological, and sustainability sources. These included regulations and documents related to veterinary, pharmaceutical, food, and feed data, as well as considerations for conservation. Weighted scores reflecting all these aspects were applied to rank the species. The assessment resulted in the creation of List A, which contains the most promising candidates for future HVMPs, and List B, which compiles plant species whose simplified registration is currently not considered a priority or is not advisable based on the available data. Eighty-three species received positive overall scores. These medicinal plants demonstrate strong regulatory recognition, pharmacopoeial inclusion, and well-documented safety profiles, highlighting their suitability for evidence-based veterinary use. The proposed framework offers a clear, reproducible method for prioritizing botanical species for regulatory consideration as HVMPs. It supports EU initiatives to enhance sustainable animal health, antimicrobial stewardship, and innovation in veterinary phytotherapy.